Oculis Shares Plunge 23% on Clinical Trial Failure and Fraud Investigation

In a move highlighting the high stakes of the biotech sector, Oculis Holding faced intense selling pressure that led to a 23% collapse in its share price. This decline followed the failure of Phase 3 trials for OCS-01 eye drops to meet primary endpoints, prompting the company to announce it will no longer pursue an FDA filing for the treatment of diabetic macular edema. Simultaneously, law firm Levi & Korsinsky initiated an investigation into potential securities fraud regarding the company's disclosures.

This clinical setback places Oculis at a disadvantage compared to its peers in the ophthalmology space; per market data, established players like Alcon and Bausch + Lomb maintain relative stability while smaller firms face extreme volatility upon trial failures. According to analyst reports, abandoning the FDA filing plans is a significant blow to the company's pipeline, as OCS-01 was previously viewed as a primary growth catalyst in a highly competitive ocular treatment market.

Investors should watch for technical support levels after OCS closed at $11.21 (close June 5, 2026), having touched a daily low of $11.17. Looking ahead at the economic calendar, broader healthcare sentiment may be influenced by Services PMI data from the US and China on June 3, which could provide signals regarding consumer spending and overall economic growth trajectories.